Scantox
- Company typePrivate
- Founded1977
- HeadquartersLille Skensved, Denmark
- Headcount101–250
- GTM typeB2B
- OfferingServices
Scantox firmographics
Firmographics- Name
- Scantox
- Legal name
- Scantox Holding Aps
- Website
- https://scantox.com
- Company type
- Private
- Founded year
- 1977
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Scantox industry classification
Industry- Product category
- Preclinical Contract Research Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)
- akta.pro secondary industries
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Nonclinical Study Management & Regulatory Writing (IND-enabling) (HLAGAFAN), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)
Keywords
Where Scantox is headquartered
LocationHeadquarters
- HQ city
- Lille Skensved
- HQ country
- Denmark
- HQ region
- Europe
Offices5 records
Markets served
Scantox business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Contract Research Services: Fee-for-service preclinical contract research including discovery services, genetic toxicology testing, regulatory toxicology studies, and pharmaceutical development/analytical services. Revenue is project-based, earned through contractual agreements with pharmaceutical, biotech, and medical device companies across all development phases from early discovery through clinical trials.
- GLP Regulatory Studies: GLP-compliant studies for regulatory submissions including genotoxicity, toxicology, and safety pharmacology studies following OECD guidelines
- GMP Manufacturing: GMP manufacture and clinical packaging services for Phase 1 and 2 clinical trials, including formulation development and analytical services
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing for pharmaceutical companies |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Scantox product offering
Product offeringCore offering
Scantox is a Nordic preclinical GLP-accredited contract research organization (CRO) providing integrated drug development services across four divisions: Discovery Services (CNS/neurology efficacy models, PK/PD, in vitro and in vivo studies via Scantox Neuro), Genetic Toxicology Services (DuplexSeq™ NGS assays, Big Blue® transgenic rodent assays, traditional genotoxicity tests), Regulatory Toxicology Services (GLP-compliant toxicology, safety pharmacology, histopathology with Göttingen Minipig expertise), and Pharmaceutical Development & Analytical Services (formulation development, GMP manufacturing, bioanalysis, clinical packaging for Phase 1/2 trials).
Product overview
Scantox is a Nordic preclinical GLP-accredited Contract Research Organization (CRO) providing integrated drug development services across four main divisions: Discovery Services (including Scantox Neuro for CNS/neurology research), Genetic Toxicology Services (featuring DuplexSeq™ Mutagenesis Assays, Big Blue®, and traditional genotoxicity assays), Regulatory Toxicology Services, and Pharmaceutical Development & Analytical Services. The company operates across multiple sites in Denmark, Sweden, Austria, and the UK following a series of strategic acquisitions including QPS Neuropharmacology, Gentronix, Solural Pharma, and Q&Q Labs AB. The integrated portfolio spans from early lead identification through regulatory safety studies to clinical trial support, enabling a 'one-stop shop' approach for pharmaceutical and biotech clients worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- DuplexSeq™ Mutagenesis Assays: Error-corrected sequencing-based mutagenesis testing assays acquired from TwinStrand Biosciences for nonclinical genomic safety assessment.
- Big Blue® Transgenic Rodent Gene Mutation Assay
- Enhanced Ames Test
Products and services
- Discovery Services Comprehensive preclinical discovery services spanning in vitro and in vivo efficacy models, specializing in neurology-related pharmaceutical research and CNS drug discovery through Scantox Neuro. Includes disease models for Alzheimer's, Parkinson's, ALS, Huntington's, lysosomal storage diseases, PK/PD studies, exploratory toxicology, and local tolerance studies for pharmaceutical and biotech clients.
- Genetic Toxicology Services Comprehensive portfolio of screening and regulatory genotoxicity products and services including mutagen testing, clastogens/aneugens assessment, and GLP-compliant studies. Includes DuplexSeq™ NGS assays, Big Blue® transgenic rodent assays, Ames tests, micronucleus assays, and mouse lymphoma assays for pharmaceutical and biotech clients.
- Regulatory Toxicology Services Full spectrum of preclinical toxicology studies including GLP compliance, general toxicology, safety pharmacology, clinical pathology, and histopathology, with leading expertise using Göttingen Minipig models for pharmaceutical and biotech regulatory submissions.
- Pharmaceutical Development & Analytical Services Formulation development, dose formulation manufacturing including GMP and clinical packaging for Phase 1 and 2 trials, bioanalysis using LC-MS, ELISA, qPCR, and Immunohistochemistry, and ICH stability testing for pharmaceutical clients.
- DuplexSeq™ Mutagenesis Assays Error-corrected next-generation sequencing-based mutagenesis testing assays providing high-precision genomic safety assessment for nonclinical drug development. Acquired from TwinStrand Biosciences, Scantox is the sole global CRO provider of this proprietary technology, enabling high-sensitivity detection of low-frequency mutations for pharmaceutical and biotech clients.
Quantifiable outcome
- Integrated genomic safety platform spanning early screening through late-stage regulatory development
- +1 more outcomes
Companies that use Scantox
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Scantox technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Scantox partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and supporting.
- LatchBiocoreLatchBio was selected to provide the cloud-based bioinformatics platform for DuplexSeq™ Mutagenesis App migration. The platform was chosen for 21 CFR Part 11 compliance, immutable audit trails, and SOC 2 Type II certified infrastructure suitable for regulated nonclinical environments. The migration restores and enhances customer access to error-corrected sequencing assays.
- Fulcrum GenomicssupportingFulcrum Genomics supported the technical migration of the DuplexSeq™ bioinformatics pipeline to the cloud-based LatchBio platform. Clint Valentine, the original pipeline architect, led the migration confirming equivalent outputs to TwinStrand's original dataset.
- LundbeckcoreScantox partnered with Lundbeck to develop a unique stress-free blood sampling method for Göttingen minipigs enabling deeper understanding of drug effects on circadian cortisol profiles. This innovation allows frequent blood sampling without causing pain or disturbance to animals, validated through 24-hour cortisol monitoring studies. The partnership resulted in a peer-reviewed publication demonstrating the model's relevance for neurological and stress disorder drug development.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Scantox competitors and assessment
Company assessmentDirect peers
- Inotiv: US-based preclinical CRO with strong toxicology, pathology, and discovery services portfolio. Closely aligned with Scantox in service mix (in vivo toxicology, safety assessment, research models), serving similar pharma/biotech clients with project-based pricing.
- QPS Holdings: Global CRO with major focus on CNS/neuropharmacology, DMPK, and bioanalysis. Directly comparable to Scantox Neuro — Scantox acquired the neuropharmacology division of QPS Austria, leaving the parent as a competing CNS specialty CRO with overlapping capabilities and clients.
Emerging players
- Pharmaron: China-headquartered CRO with rapidly expanding preclinical, DMPK, toxicology, and bioanalytical services. Comparable to Scantox in integrated preclinical offering, with aggressive European/US expansion strategy competing for the same pharma outsourcing wallet.
- Frontage Laboratories: US/China-based CRO offering bioanalytical, preclinical, and CMC services. Overlaps with Scantox's bioanalytical and formulation development capabilities (added via Q&Q Labs and Solural Pharma acquisitions) and competes for similar biotech and specialty pharma clients.
- Toxikon (formerly Bionique Labs / Marshall BioResources-adjacent): US-based preclinical contract research organization focused on toxicology and medical device safety testing. Comparable to Scantox's regulatory toxicology and local tolerance/biocompatibility service lines, serving overlapping medical device and pharma clients.
Broad incumbents
- Charles River Laboratories: Global preclinical CRO with deep toxicology, safety assessment, and discovery capabilities. Highly comparable to Scantox's GLP toxicology and discovery services but at vastly larger scale and broader geographic footprint; sets the pricing/quality benchmark Scantox must compete against.
- WuXi AppTec: China-headquartered CRO with comprehensive preclinical toxicology, DMPK, and bioanalytical services. Competes for the same global pharma outsourcing budget as Scantox, particularly in genetic toxicology and discovery toxicology, and serves as a major non-European comparator.
- Labcorp Drug Development (formerly Covance): One of the largest CROs globally with extensive preclinical toxicology, genetic toxicology, and central laboratory services. Overlaps directly with Scantox's regulatory toxicology and genetic toxicology offerings, plus broader Phase 1 clinical packaging services.
- Eurofins Scientific: Global testing services giant with significant pharmaceutical and genetic toxicology testing operations. Comparable to Scantox on the testing/analytical side, with overlapping GLP genotoxicity and bioanalytical services, though broader scope and global reach.
Regional players
- ITR Laboratories Canada: Canadian preclinical CRO specializing in toxicology, safety pharmacology, and bioanalysis. Comparable to Scantox's regulatory toxicology division in service mix, serving pharma/biotech clients primarily in North America — a regional alternative rather than direct head-to-head European competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks4 records
Key highlights7 records
Customer concentration
Scantox social profiles
Digital presenceScantox compliance and trust
Trust signalCompliance2 records
Scantox financial estimates
Financial estimateRevenue estimate
Valuation estimate
Scantox leadership team
Management profileNumber of profiles
Profiles10 records
Scantox subsidiaries and ownership
Company hierarchySubsidiaries6 records
Scantox funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Scantox M&A and investment
M&A and investmentM&A5 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Scantox
What does Scantox do?
Scantox is a Nordic preclinical GLP-accredited contract research organization (CRO) providing integrated drug development services across four divisions: Discovery Services (CNS/neurology efficacy models, PK/PD, in vitro and in vivo studies via Scantox Neuro), Genetic Toxicology Services (DuplexSeq™ NGS assays, Big Blue® transgenic rodent assays, traditional genotoxicity tests), Regulatory Toxicology Services (GLP-compliant toxicology, safety pharmacology, histopathology with Göttingen Minipig expertise), and Pharmaceutical Development & Analytical Services (formulation development, GMP manufacturing, bioanalysis, clinical packaging for Phase 1/2 trials).
Is Scantox a public or private company?
Scantox is a private company. It is classified as private equity controlled and is currently operating.
When was Scantox founded?
Scantox was founded in 1977. It employs 101 to 250 people.
Where is Scantox based?
Scantox is headquartered in Lille Skensved, Denmark, in the Europe region.
How does Scantox make money?
Three revenue lines are on record. Contract Research Services are the primary driver. The others are GLP Regulatory Studies and GMP Manufacturing.
Who are Scantox's main competitors?
Direct peers on record are Inotiv and QPS Holdings. Emerging players are Pharmaron, Frontage Laboratories and Toxikon (formerly Bionique Labs / Marshall BioResources-adjacent). Broad incumbents are Charles River Laboratories, WuXi AppTec, Labcorp Drug Development (formerly Covance) and Eurofins Scientific. ITR Laboratories Canada is listed as a regional player.
Does Scantox have an API?
No public API is recorded for Scantox.
What industry is Scantox in?
Scantox's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP), with a secondary code of HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK). Its NAICS code is 5417 and its SIC code is 8731.